Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03646604 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Upadacitinib in Pediatric Participants With Severe Atopic Dermatitis
A Phase 1 study, sponsored by AbbVie.
- Completed
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
NCT03646604 is a Phase 1 study that has completed, run by AbbVie. The registered enrollment target is 35 participants.
The verdict
NCT03646604, a Phase 1 study, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate the safety, pharmacokinetics and tolerability of multiple doses of upadacitinib in pediatric participants with severe atopic dermatitis and to evaluate palatability of upadacitinib oral solution in pediatric participants.
Interventions
- DRUG Upadacitinib (ABT-494)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2019-01-31 |
| Est. Completion | 2024-08-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03646604
The ClinicalTrials.gov registry entry for NCT03646604 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Upadacitinib (ABT-494) is the first listed.
NCT03646604 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03646604 about?
NCT03646604 is a clinical study titled "A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Upadacitinib in Pediatric Participants With Severe Atopic Dermatitis". The objective of this study is to evaluate the safety, pharmacokinetics and tolerability of multiple doses of upadacitinib in pediatric participants with severe atopic dermatitis and to evaluate palatability of upadacitinib oral solution in pediatric participants.
What is the current status of trial NCT03646604?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2019-01-31. Estimated completion is 2024-08-29.
What interventions are being tested in trial NCT03646604?
The interventions under investigation include: Upadacitinib (ABT-494) (DRUG).
Who is sponsoring clinical trial NCT03646604?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.